1Buchbinder R,Osborne RH,Ebeling PR,et al.A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures.N Engl J Med,2009,361(6):557 -568.
2Wardlaw D,Cummings SR,Van Meirhaeghe J,et al.Efficacy and safety of balloon kyphoplasty compared with non -surgical care for vertebral compression fracture (FREE):a randomised controlled trial.Lancet,2009,373(9668):1016-1024.
5Taylor RS,Taylor RJ,Fritzell P.Balloon kyphoplasty and vertebroplasty for vertebral compression fractures:a comparative systematic review of efficacy and safety.Sipine,2006,31 (23):2747 -2755.
5Galibert P,Deramond H,Rosat P,et al.Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty.Neurochirurgie,1987,33 (2):166-168.
6Kaemmerlen P,Thiesse P,Bouvard H,et al.Percutaneous vertebroplasty in the treatment of metastases:technique and results.J Radiol,1989,70(10):557 -562.
7Cotten A,Dewatre F,Cortet B,et al.Percutaneous vertebroplasty for osteolytic metastases and myloma; effects of the percentage of lesion filling and leakage of methyl methacrylate at clinical follow2up.Radiology,1996,200(2):525-530.
8Garfin SR,Yuan HA,Reiley MA,et al.Kyphoplasty and vertebroplasty for the treatment of painful osteoporotic vertebral compression fracture.Spine,2001,26(14):1511 -1515.
9Oh GS,Kim HS,Ju CI.Comparison of the results of balloon kyphoplasty performed at different times after injury.J Korean Neurosurg Soc,2010,47(3):199 -202.
10Iida K,Sudo A,Ishiguro S.Clinical and radiological results of calcium phosphate cement-assisted balloon osteoplasty for Colles' fractures in osteoporotic senile female patients.J Orthop Sci,2010,15(2):204 -209.
4Reginster J, Minne HW, Sorensen OH, et al. Randomized trial ofthe effects of risedronate on vertebral fractures in women withestablished postmenopausal osteoporosis. Vertebral Efficacy withRisedronate Therapy (VERT) Study Group. Osteoporos Int, 2000,11(1): 83-91.
5Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into ac-tions of bisphosphonates on bone: differences in interactions withhydroxy apatite. Bone, 2006, 38(5): 617-627.
6Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and phar-macodynamics of zoledronic acid in cancer patients with bonemetastases. J Clin Pharmacol, 2002, 42(11): 1228-1236.
7Black DM, Delmas PD, EastellR, et al. Once-yearly zoledronicacid for treatment of postmenopausal osteoporosis. N Engl J Med,2007,356(18): 1809-1822.
8Lyles KW,Col6n-Emeric CS, Magaziner JS, et al. Zoledronic acidand clinical fractures and mortality after hip fracture. N Engl JMed, 2007, 357(18): 1799-1809.
9Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture effi-cacy and reduction of mortality in relation to timing of the firstdose of zoledronic acid after hip fracture. J Bone Miner Res,2009,24(7): 1308-1313.
10Colon-Emeric C, Nordsletten L, Olson S, et al. Association be-tween timing of zoledronic acid infusion and hip fracture healing.Osteoporos Int, 2011,22(8): 2329-2336...
